Response criteria in systemic mastocytosis: moving forward with practical assessment that reflects meaningful health outcome
Animesh Pardanani,
Animesh Pardanani
Division of Hematology and Department of Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this author Ayalew Tefferi,
Ayalew Tefferi
Division of Hematology and Department of Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this author
Animesh Pardanani,
Animesh Pardanani
Division of Hematology and Department of Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this author Ayalew Tefferi,
Ayalew Tefferi
Division of Hematology and Department of Medicine, Mayo Clinic, Rochester, MN, USA
Search for more papers by this author
First published: 15 June 2010
Animesh Pardanani, MBBS, PhD, Division of Hematology and Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 5505, USA.Tel: 507-284-3417; Fax: 507-266-49972;e-mail:
[email protected] No abstract is available for this article.
Reference
- 1
Lim KH,
Tefferi A,
Lasho TL,
Finke C,
Patnaik M,
Butterfield JH,
McClure RF,
Li CY,
Pardanani A,
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.
Blood
2009; 113: 5727–36.
